Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells.

Chemotherapy of prostate cancer targets androgen receptor (AR) by androgen ablation or antiandrogens, but unfortunately, it is not curative. Our attack on prostate cancer envisions the proteolytic elimination of AR, which requires a fuller understanding of AR turnover. We showed previously that calmodulin (CaM) binds to AR with important consequences for AR stability and function. To examine the involvement of Ca(2+)/CaM in the proteolytic breakdown of AR, we analyzed LNCaP cell extracts that bind to a CaM affinity column for the presence of low molecular weight forms of AR (intact AR size, approximately 114 kDa). Using an antibody directed against the NH(2)-terminal domain (ATD) of AR on Western blots, we identified approximately 76-kDa, approximately 50-kDa, and 34/31-kDa polypeptides in eluates of CaM affinity columns, suggesting the presence of CaM-binding sites within the 31/34-kDa ATD of AR. Under cell-free conditions in the presence of phenylmethylsulfonyl fluoride, AR underwent Ca(2+)-dependent degradation. AR degradation was inhibited by N-acetyl-leu-leu-norleu, an inhibitor of thiol proteases, suggesting the involvement of calpain. In intact cells, AR breakdown was accelerated by raising intracellular Ca(2+) using calcimycin, and increased AR breakdown was reversed with the cell-permeable Ca(2+) chelator bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra-(acetoxymethyl)-ester. In CaM affinity chromatography studies, the Ca(2+)-dependent protease calpain was bound to and eluted from the CaM-agarose column along with AR. Caspase-3, which plays a role in AR turnover under stress conditions, did not bind to the CaM column and was present in the proenzyme form. Similarly, AR immunoprecipitates prepared from whole-cell extracts of exponentially growing LNCaP cells contained both calpain and calpastatin. Nuclear levels of calpain and calpastatin (its endogenous inhibitor) changed in a reciprocal fashion as synchronized LNCaP cells progressed from G(1) to S phase. These reciprocal changes correlated with changes in AR level, which increased in late G(1) phase and decreased as S phase progressed. Taken together, these observations suggest potential involvement of AR-bound CaM in calcium-controlled, calpain-mediated breakdown of AR in prostate cancer cells.

[1]  F. Sarkar,et al.  Regulatory processes affecting androgen receptor expression, stability, and function: Potential targets to treat hormone‐refractory prostate cancer , 2006, Journal of cellular biochemistry.

[2]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[3]  G. Wang,et al.  Amino‐terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer , 2006, Journal of cellular biochemistry.

[4]  I. McEwan,et al.  Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. , 2005, Molecular endocrinology.

[5]  D. Neal,et al.  Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation , 2005, Nucleic acids research.

[6]  R. Kuefer,et al.  Cleavage of β-Catenin by Calpain in Prostate and Mammary Tumor Cells , 2004, Cancer Research.

[7]  M. Menon,et al.  Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. E. Goll,et al.  Interaction of calpastatin with calpain: a review , 2004, Biological chemistry.

[9]  L. Ellerby,et al.  Kennedy's Disease , 2003, Journal of Biological Chemistry.

[10]  Chawnshang Chang,et al.  Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication , 2003 .

[11]  M. Menon,et al.  Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase , 2003, Journal of cellular physiology.

[12]  D. Boothman,et al.  μ-Calpain Activation in β-Lapachone-Mediated Apoptosis , 2003 .

[13]  Chawnshang Chang,et al.  Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  L. Ellerby,et al.  Kennedy’s Disease PHOSPHORYLATION OF THE POLYGLUTAMINE-EXPANDED FORM OF ANDROGEN RECEPTOR REGULATES ITS CLEVAGE BY CASPASE-3 AND ENHANCES CELL DEATH* , 2003 .

[15]  O. Jänne,et al.  Involvement of Proteasome in the Dynamic Assembly of the Androgen Receptor Transcription Complex* , 2002, The Journal of Biological Chemistry.

[16]  Chawnshang Chang,et al.  Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[17]  Chawnshang Chang,et al.  Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase , 2002, The EMBO journal.

[18]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[19]  E. Wilson,et al.  The putative androgen receptor-A form results from in vitro proteolysis. , 2001, Journal of molecular endocrinology.

[20]  K. Burnstein,et al.  The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer. , 2001, Endocrinology.

[21]  D. Edwards,et al.  Erratum: A c619y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) (Molecular Endocrinology (1999) 13 (2065-2075)) , 2000 .

[22]  B. Keegan,et al.  Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. , 2000, Biochemical and biophysical research communications.

[23]  N. Prevarskaya,et al.  Store depletion and store‐operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis , 2000, The Journal of physiology.

[24]  J. A. Kemppainen,et al.  FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor* , 2000, The Journal of Biological Chemistry.

[25]  R. M. Sharrard,et al.  Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. , 2000, Journal of molecular endocrinology.

[26]  R. Huber,et al.  The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Edwards,et al.  A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) , 1999, Molecular endocrinology.

[28]  Z. Wang,et al.  Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells. , 1999, Cancer research.

[29]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[30]  G. Sobue,et al.  Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. , 1998, Biochemical and biophysical research communications.

[31]  M. Molinari,et al.  Calpain: a protease in search of a function? , 1998, Biochemical and biophysical research communications.

[32]  C. Bucana,et al.  Aloe barbadensis extracts reduce the production of interleukin-10 after exposure to ultraviolet radiation. , 1998, The Journal of investigative dermatology.

[33]  Dale E. Bredesen,et al.  Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.

[34]  L. Santella The role of calcium in the cell cycle: facts and hypotheses. , 1998, Biochemical and biophysical research communications.

[35]  H. Schipper,et al.  Spinobulbar muscular atrophy: polyglutamine-expanded androgen receptor is proteolytically resistant in vitro and processed abnormally in transfected cells. , 1998, Human molecular genetics.

[36]  P. Leigh,et al.  Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. , 1998, Human molecular genetics.

[37]  J. Isaacs,et al.  Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin , 1997, The Prostate.

[38]  S. Piantadosi,et al.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  E. Mulder,et al.  Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited Trypsinization , 1995, The Journal of Biological Chemistry.

[40]  D. Tindall,et al.  Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. , 1995, Endocrinology.

[41]  O. Jänne,et al.  Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. , 1994, Endocrinology.

[42]  J. Trapman,et al.  Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. , 1993, The Biochemical journal.

[43]  A. Brinkmann,et al.  Androgen receptor heterogeneity in LNCaP cells is caused by a hormone independent phosphorylation step , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  C. Subramanyam,et al.  Nuclear localization of 68 kDa calmodulin‐binding protein is associated with the onset of DNA replication , 1990, Journal of cellular physiology.

[45]  J. Trapman,et al.  Androgen receptor heterogeneity and phosphorylation in human LNCaP cells. , 1990, Biochemical and biophysical research communications.

[46]  K. Wang,et al.  Calmodulin-binding proteins as calpain substrates. , 1989, The Biochemical journal.

[47]  A. Brinkmann,et al.  Analysis of steroid- and DNA-binding domains of the calf uterine androgen receptor by limited proteolysis. , 1987, Journal of steroid biochemistry.

[48]  H. Kawasaki,et al.  Isolation and sequence analyses of cDNA clones for the large subunits of two isozymes of rabbit calcium-dependent protease. , 1986, The Journal of biological chemistry.

[49]  H. Kawasaki,et al.  Isolation and sequence analysis of cDNA clones for the small subunit of rabbit calcium-dependent protease. , 1986, The Journal of biological chemistry.

[50]  B. O’Malley,et al.  Progesterone-binding components of chick oviduct: partial purification and characterization of a calcium-activated protease which hydrolyzes the progesterone receptor. , 1980, Biochemistry.

[51]  F. S. French,et al.  Effects of proteases and protease inhibitors on the 4.5 S and 8 S androgen receptor. , 1979, The Journal of biological chemistry.

[52]  F. Bresciani,et al.  Estrogen binding proteins of calf uterus. Molecular and functional characterization of the receptor transforming factor: A Ca2+-activated protease. , 1977, The Journal of biological chemistry.